The Effect of Irisin on Thyroid Hormone Levels in Chronic Paroxetine-Treated Rats.
Irisin
Paroxetine
Thyroid-stimulating hormone
Thyroxin
Triiodothyronine
Journal
Biological trace element research
ISSN: 1559-0720
Titre abrégé: Biol Trace Elem Res
Pays: United States
ID NLM: 7911509
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
10
01
2022
accepted:
14
03
2022
pubmed:
25
3
2022
medline:
21
1
2023
entrez:
24
3
2022
Statut:
ppublish
Résumé
It is known that serotonin reuptake inhibitors (SSRIs), which are widely used in mood disorders, affect the hypothalamic-pituitary-thyroid axis activity. In this study, we investigated the effect of paroxetine, an SSRI, on thyroid hormone levels in rats. We also examined the role of irisin, a newly discovered potential regulatory hormone for metabolism, on paroxetine-induced changes. A total of 64 Sprague-Dawley female and male rats were randomly divided into four subgroups for each gender and treated as follows: sham-operated control (vehicle), paroxetine (treated with 20 mg/kg paroxetine by oral gavage), irisin (100 ng/kg/day for 28 days with mini-osmotic pumps), and paroxetine + irisin group (n = 8). Serum fasting free triiodothyronine (fT3) and free thyroxine (fT4) levels were measured by automated chemiluminescence method. Serum thyroid-stimulating hormone (TSH) level was determined with enzyme-linked immunosorbent analysis (ELISA). Compared to the sham control group (p < 0.05), the significantly reduced fT4 and TSH serum levels in paroxetine-treated male animals were markedly increased by subcutaneous irisin perfusion. fT3 levels significantly increased in both irisin (4.35 ± 0.17 pq/mL) and paroxetine + irisin groups (4.51 ± 0.19 pq/mL) compared to sham control (3.60 ± 0.23 pq/mL) and paroxetine groups (3.57 ± 0.12 pq/mL) (p < 0.05). It was observed that serum fT3, fT4, and TSH levels decreased in female animals receiving paroxetine compared to the sham control group. Subcutaneous administration of irisin increased these hormone levels. However, these changes were not statistically significant. These results suggested that irisin may play a role in the mechanism underlying the beneficial effects of exercise in preventing SSRI-related side effects by increasing thyroid hormone levels, which were decreased by paroxetine.
Identifiants
pubmed: 35322355
doi: 10.1007/s12011-022-03204-8
pii: 10.1007/s12011-022-03204-8
doi:
Substances chimiques
Fibronectins
0
Paroxetine
41VRH5220H
Thyroxine
Q51BO43MG4
Thyroid Hormones
0
Triiodothyronine
06LU7C9H1V
Thyrotropin
9002-71-5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
810-815Subventions
Organisme : The Scientific and Technological Research Council of Turkey
ID : 118S519
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Kirkegaard C, Faber J (1998) The role of thyroid hormones in depression. Eur J Endocrinol 138(1):1–9
doi: 10.1530/eje.0.1380001
Loosen PT (1986) Hormones of the hypothalamic-pituitary-thyroid axis: a psychoneuroendocrine perspective. Pharmacopsychiatry 19(6):401–415
doi: 10.1055/s-2007-1017278
Karakatsoulis GN, Tsapakis E-M, Mitkani C, Fountoulakis KN (2021) Subclinical thyroid dysfunction and major depressive disorder. Hormones 20(4):613–621
doi: 10.1007/s42000-021-00312-3
Duval F (2018) Thyroid hormone treatment of mood disorders. Current Treatment Options in Psychiatry 5(4):363–376
doi: 10.1007/s40501-018-0155-z
Trifu SC, Tudor A, Radulescu I (2020) Aggressive behavior in psychiatric patients in relation to hormonal imbalance. Exp Ther Med 20(4):3483–3487
Ferguson JM (2001) SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 3(1):22–27
doi: 10.4088/PCC.v03n0105
Bourin M, Chue P, Guillon Y (2001) Paroxetine: a review. CNS Drug Rev 7(1):25–47
doi: 10.1111/j.1527-3458.2001.tb00189.x
Harel Z, Biro FM, Tedford WL (1995) Effects of long term treatment with sertraline (Zoloft®) simulating hypothyroidism in an adolescent. J Adolesc Health 16(3):232–234
doi: 10.1016/1054-139X(94)00069-Q
Gitlin M, Altshuler LL, Frye MA, Suri R, Huynh EL, Fairbanks L, Bauer M, Korenman S (2004) Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors. J Psychiatry Neurosci 29(5):383
Šagud M, Pivac N, Mück-Šeler D, Jakovljević M, Mihaljević-Peleš A, Koršić M (2002) Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Neuropsychobiology 45(3):139–143
doi: 10.1159/000054954
Gendall KA, Joyce PR, Mulder RT, Luty SE (2003) Thyroid indices and response to fluoxetine and nortriptyline in major depression. J Psychopharmacol 17(4):431–437
doi: 10.1177/0269881103174001
Shelton RC, Winn S, Ekhatore N, Loosen PT (1993) The effects of antidepressants on the thyroid axis in depression. Biol Psychiat 33(2):120–126
doi: 10.1016/0006-3223(93)90311-Z
König F, Hauger B, von Hippel C, Wolfersdorf M, Kaschka WP (2000) Effect of paroxetine on thyroid hormone levels in severely depressed patients. Neuropsychobiology 42(3):135–138
doi: 10.1159/000026683
Caye A, Pilz LK, Maia AL, Hidalgo MP, Furukawa TA, Kieling C (2020) The impact of selective serotonin reuptake inhibitors on the thyroid function among patients with major depressive disorder: a systematic review and meta-analysis. Eur Neuropsychopharmacol 33:139–145
doi: 10.1016/j.euroneuro.2020.01.011
Hulbert AJ (2000) Thyroid hormones and their effects: a new perspective. Biol Rev Camb Philos Soc 75(4):519–631
doi: 10.1017/S146479310000556X
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ (2012) A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382):463–468
doi: 10.1038/nature10777
De Leo S, Lee SY, Braverman LE (2016) Hyperthyroidism. Lancet (London, England) 388(10047):906–918
doi: 10.1016/S0140-6736(16)00278-6
Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Makras P, Perakakis N, Kountouras J, Mantzoros CS (2018) Irisin in metabolic diseases. Endocrine 59(2):260–274
doi: 10.1007/s12020-017-1476-1
Crujeiras AB, Pardo M, Casanueva FF (2015) Irisin: ‘fat’ or artefact. Clin Endocrinol 82(4):467–474
doi: 10.1111/cen.12627
Atici E, Mogulkoc R, Baltaci AK, Menevse E: Both hypothyroidism and hyperthyroidism increase plasma irisin levels in rats. Hormone molecular biology and clinical investigation 2017, 33(3).
Samy DM, Ismail CA, Nassra RA: Circulating irisin concentrations in rat models of thyroid dysfunction—effect of exercise. Metabolism: clinical and experimental 2015, 64(7):804–813.
Ruchala M, Zybek A, Szczepanek-Parulska E (2014) Serum irisin levels and thyroid function–newly discovered association. Peptides 60:51–55
doi: 10.1016/j.peptides.2014.07.021
Ates İ, Altay M, Topcuoglu C, Yılmaz FM (2016) Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Archives of endocrinology and metabolism 60(2):95–100
doi: 10.1590/2359-3997000000077
Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M (2016) Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 67(5):476–480
doi: 10.5603/EP.a2016.0030
Tekin S, Erden Y, Ozyalin F, Onalan EE, Cigremis Y, Colak C, Tekedereli I, Sandal S (2018) Central irisin administration suppresses thyroid hormone production but increases energy consumption in rats. Neurosci Lett 674:136–141
doi: 10.1016/j.neulet.2018.03.046
Ruchala M, Zybek A, Szczepanek-Parulska E (2014) Serum irisin levels and thyroid function—newly discovered association. Peptides 60:51–55
doi: 10.1016/j.peptides.2014.07.021
Shan D, Zou L, Liu X, Cai Y, Dong R, Hu Y: Circulating irisin level and thyroid dysfunction: a systematic review and meta-analysis. BioMed Research International 2020, 2020.
Irrcher I, Adhihetty PJ, Sheehan T, Joseph A-M, Hood DA (2003) PPARγ coactivator-1α expression during thyroid hormone-and contractile activity-induced mitochondrial adaptations. Am J Physiol Cell Physiol 284(6):C1669–C1677
doi: 10.1152/ajpcell.00409.2002
Canpolat S, Ulker N, Yardimci A, Tancan E, Sahin E, Yaman SO, Bulmuş O, Alver A, Ozcan M: Irisin ameliorates male sexual dysfunction in paroxetine-treated male rats. Psychoneuroendocrinology 2021:105597.
Abdel-Dayem MM, Elgendy MS (2009) Effects of chronic estradiol treatment on the thyroid gland structure and function of ovariectomized rats. BMC Res Notes 2(1):1–7
doi: 10.1186/1756-0500-2-173
Araujo LFBd, Soares Jr JM, Simões RS, Calió PL, Oliveira-Filho RM, Simões MdJ, Haidar MA, Baracat EC: Effect of conjugated equine estrogens and tamoxifen administration on thyroid gland histomorphology of the rat. Clinics 2006, 61:321–326.
Schindler A (2003) Thyroid function and postmenopause. Gynecol Endocrinol 17(1):79–85
doi: 10.1080/gye.17.1.79.85
Arafah BM (2001) Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 344(23):1743–1749
doi: 10.1056/NEJM200106073442302
Brosse AL, Sheets ES, Lett HS, Blumenthal JA (2002) Exercise and the treatment of clinical depression in adults: recent findings and future directions. Sports medicine (Auckland, NZ) 32(12):741–760
doi: 10.2165/00007256-200232120-00001
Silva JE (1995) Thyroid hormone control of thermogenesis and energy balance. Thyroid : official journal of the American Thyroid Association 5(6):481–492
doi: 10.1089/thy.1995.5.481
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39:125–130
doi: 10.1016/j.peptides.2012.11.014
Ellefsen S, Vikmoen O, Slettaløkken G, Whist JE, Nygaard H, Hollan I, Rauk I, Vegge G, Strand TA, Raastad T et al (2014) Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur J Appl Physiol 114(9):1875–1888
doi: 10.1007/s00421-014-2922-x